logo

News

IOmet Pharma announces the appointment of Rakesh Patel as a Non-Executive Director

Edinburgh, UK, April 15, 2015 – IOmet Pharma, a privately-held company focused on cancer immunotherapy and cancer metabolism, today announces the appointment of Rakesh Patel as a Non-Executive Director.  Mr Patel will join the Board of Directors with immediate effect. Mr Patel is currently a Managing Director and Co-Head of European Healthcare Banking at J.P. Morgan in London. He joined J.P. Morgan in 2008 from Novartis where he was Global Head of M&A for Novartis Pharma AG. Prior to joining […]

IOmet Phama to present data on pre-clinical cancer immunotherapy programs at AACR Annual Meeting 2015, Philadelphia

IOmet Pharma demonstrates superior in vivo PK/PD properties in pre-clinical IDO1, TDO and Dual IDO1/TDO cancer immunotherapy programs Data to be presented April 22 at American Association for Cancer Research 2015 Annual Meeting Edinburgh, UK, April 13, 2015 – IOmet Pharma, a privately-held company focused on cancer immunotherapy and cancer metabolism, will present data demonstrating superior properties of its novel, pre-clinical IDO1, TDO and IDO1/TDO Dual Inhibitor programs. The data will be presented at the American Association for Cancer Research […]

IOmet Pharma to present data on pre-clinical cancer immunotherapy programs at ITOC-2, Munich

Data to be presented March 25 at Immunotherapy of Cancer Conference, Munich, Germany Edinburgh, UK, March 24, 2015 – IOmet Pharma, a privately-held company focused on cancer immunotherapy and cancer metabolism, will present data demonstrating superior pharmacokinetic / pharmacodynamic (PK/PD) properties in its pre-clinical IDO, TDO and IDO/TDO Dual Inhibitor programs. The data will be presented at the Immunotherapy of Cancer (ITOC) meeting in Munich, Germany on March 25 & 26. IOmet is developing multiple, distinct novel chemical series of […]

IOmet Pharma demonstrates superior in vivo PK/PD properties in pre-clinical IDO, TDO and Dual IDO/TDO cancer immunotherapy programs

Data presented today at Keystone Tumor Immunology Symposium, Banff, Canada Edinburgh, UK, February 10, 2015 – IOmet Pharma, a privately-held company focused on cancer immunotherapy and cancer metabolism, today presented data demonstrating superior pharmacokinetic / pharmacodynamic (PK/PD) properties in its pre-clinical IDO, TDO and IDO/TDO Dual Inhibitor programs. The data was presented at the Keystone Tumor Immunology Symposium in Banff, Alberta, Canada. IOmet is developing multiple, distinct novel chemical series of potent, IDO-selective, TDO-selective and dual-acting IDO/TDO inhibitors. IDO (indoleamine-2,3-dioxygenase) […]

IOmet Pharma to present data on pre-clinical cancer immunotherapy programs at Keystone Tumor Immunology Symposium

Edinburgh, UK, February 6, 2015 – IOmet Pharma, a privately-held company focused on cancer immunotherapy and cancer metabolism, will present data on its preclinical IDO, TDO and IDO/TDO Dual Inhibitor programs at the Keystone Tumor Immunology Symposium in Banff, Alberta, Canada, on February 10, 2015. IOmet has identified multiple, distinct novel chemical series of potent, IDO-selective, TDO-selective and dual-acting IDO/TDO inhibitors. These compounds demonstrate highly favourable in vitro human and rodent PK properties, which translate to robust in vivo PK/PD […]

IOmet Pharma Presents GLUT1 Program at EORTC-NCI-AACR Symposium 2014 in Barcelona

IOmet Head of Biology, Dr Alan Wise, provides oral presentation of IOmet’s preclinical GLUT1 Inhibitor program at the 2014 EORTC-NCI-AACR symposium in Barcelona on Nov 19 2014

IOmet Pharma Presents GLUT1 Program at ELRIG Drug Discovery 2014

IOmet presents poster describing preclinical GLUT1 Inhibitor program at ELRIG 2014, Sep 2-3 2014, in Manchester

IOmet Pharma Presents GLUT1 Program at Keystone Tumor Metabolism Symposium 2014

IOmet presents poster describing preclinical GLUT1 Inhibitor program at Keystone Tumor Metabolism symposium, Mar 16-20 2014, in Whistler, BC, Canada